Tiziana Life Sciences Ltd
TLSA$160M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLONDON, ENGLAND9 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Apr 30, 2026
TomorrowMarket Overview
Stock performance and key metrics
TLSA News
Catalyst Timeline
2 upcoming, 0 past
Phase 2Next
Foralumab TZLS-401 100 µg Phase 2 Results Expected
Apr 30, 2026EstimatedForalumab TZLS-401 100 µg55
Primary completion for Foralumab TZLS-401 100 µg trial (NCT06890923) in Non-Active Secondary Progressive Multiple Sclerosis
Source1 more catalyst beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Drug Pipeline
Foralumab Nasal
Multiple System Atrophy
Foralumab
Secondary Progressive Multiple Sclerosis
Foralumab TZLS-401 100 µg
Non-Active Secondary Progressive Multiple Sclerosis
Milciclib maleate
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Foralumab Nasal | Phase 2 | Multiple System Atrophy | - | - |
Foralumab | Phase 2 | Secondary Progressive Multiple Sclerosis | - | - |
Foralumab TZLS-401 100 µg | Phase 2 | Non-Active Secondary Progressive Multiple Sclerosis | - | - |
Milciclib maleate | Phase 2 | Hepatocellular Carcinoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply